The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models
首创的 ERK 抑制剂 ulixertinib 在丝裂原活化蛋白激酶 (MAPK) 驱动的儿童低级别胶质瘤模型中表现出良好的活性
期刊:Neuro-Oncology
影响因子:16.4
doi:10.1093/neuonc/noac183
Romain Sigaud, Lisa Rösch, Charlotte Gatzweiler, Julia Benzel, Laura von Soosten, Heike Peterziel, Florian Selt, Sara Najafi, Simay Ayhan, Xenia F Gerloff, Nina Hofmann, Isabel Büdenbender, Lukas Schmitt, Kathrin I Foerster, Jürgen Burhenne, Walter E Haefeli, Andrey Korshunov, Felix Sahm, Cornelis M
